林东昕: E-mail: E-mail: dlin@public.bta.net
Single Nucleotide Polymorphism in ERCC6 (C6530G) Predicts Outcome of LD Stage Small
Cell Lung Cancer Patients Treated with Carboplatin-Etoposide
LIU Ju, ZHANG
Xue-mei, ZHANG Xiang-ru, YUAN Peng
，
XU Bing-he, Lin Dong-xin (
1
Department of
Medical Oncology,
2
Department of Etiology and Carcinogenesis, Cancer Hospital
and Institute, Chinese Academy of Medical Sciences and Peking Union Medical
College, Beijing, China)
Correspondence to: XU Bing-he E-mail: Binghexu@medmail.com.cn
Lin Dong-xin E-mail:
dlin@public.bta.net.
[Abstract] Purpose:
Our research explores whether ERCC6 C6530G
polymorphism is associated with response and outcome of small cell lung cancer
(SCLC) patients treated with carboplatin and etoposide (CE) regimen. Methods: In
this retrospective study, 95 patients with limited stage SCLC were assessed for overall
survival, response rate, and time to progression (TTP) according to ERCC6 C6530G
genotypes, which were analyzed by PCR based-restriction fragment length
polymorphism (RFLP) assays. Chi-square test and single variant Kaplan-Meier
log-rank test were used to analyze data. All statistical tests were two-sided tests.
Results: Response rate for patients with CC, CG and GG genotypes were
88.9%，
90.3% and 85.7% respectively (P=1.0). ERCC6 C6530G genotypes and surgical
resection were prognostic factors for SCLC patients treated with CE regimen. Patients
with ERCC6 CG or GG genotype had a median survival of 24 months (95% CI =
18.4-29.6) that was significantly longer than those with the CC genotype (16 month,
95% CI = 9.9-22.0; P < 0.05). Median overall survival of patients underwent surgical
resection had not reached when median follow-up was 28.5 months that was
significantly longer than 18 month (95%CI = 12.5-23.5) for patients without surgical
resection (P < 0.01). Response rates for the CG, GG, and CC genotypes were 88.9,
90.3%, and 85.7%, respectively (P = 0.94). Median TTP for the CG + GG and CC
genotype groups were 13 months (95% CI = 7.3-10.6) and 9 months (95%CI =
9.2-16.8; P = 0.19)。Conclusions: ERCC6 C6530G SNP might predict treatment
outcome in CE regimen-treated SCLC patients. The patients with CG or GG genotype
had better survival than patients with the CC genotype.
[Key words] small cell lung cancer; ERCC6; single nucleotide polymorphism;
carboplatin; etoposide; prognosis; chemotherapy
http://www.paper.edu.cn
